Shots:

• The BLA submission is based on two studies assessing ABP 798 vs Rituxan which resulted in analytical- PK and clinical data showing no clinically meaningful differences between products
• In Dec- 2011 Amgen and Allergan globally collaborated to develop and commercialize four oncology antibody biosimilar medicines
• ABP 798 is a mAb CD20-directed cytolytic mAb approved for RA- non-Hodgkin's lymphoma- chronic lymphocytic leukemia (CLL) in the US and EU. Additionally- Amgen has 10 biosimilars in its portfolio four approved in the US and three in EU

Click here to read full press release/ article | Ref: Amgen | Image: Behance